Choose your country to see the products for your location
SALSA® MLPA® Probemix ME028 Prader-Willi/Angelman detects copy number variations and methylation status of the 15q11 region.
Contents: 49 MLPA probes, including 36 for the 15q11-q13 region, of which 8 provide information on the methylation status.
Tissue: genomic DNA isolated from human peripheral whole blood or specified prenatal samples (see Intended Purpose).
Application: Prader-Willi syndrome (PWS), Angelman syndrome (AS), and 15q11 duplication syndrome.
CE-marked and registered for in vitro diagnostic (IVD) use in selected territories.
The SALSA MLPA Probemix ME028 Prader-Willi/Angelman is an in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative assay for the detection of copy number variations and methylation status of the 15q11 region in genomic DNA isolated from human peripheral whole blood specimens, or in case of extracted DNA from prenatal samples, from (1) (un)cultured amniotic fluid obtained in week 16 of the pregnancy or later and free from blood contamination, (2) (un)cultured chorionic villi free from maternal contamination (copy number only), (3) fetal blood. ME028 Prader-Willi/Angelman is intended to confirm a potential cause for and clinical diagnosis of Prader-Willi syndrome (PWS), Angelman syndrome (AS), and 15q11 duplication syndrome. In rare cases, this product can also be used for carrier testing of at-risk family members.
For the full intended purpose, see the product description.
Genomic imprinting is the monoallelic expression of genes, dependent on the parental origin of the chromosome. It plays a role in growth and development. Differentially methylated regions (DMRs) act as imprinting control regions to regulate the expression of imprinted genes. Imprinting disorders like Prader-Willi syndrome (PWS) and Angelman syndrome (AS) originate from a disturbance in this monoallelic expression by disruption or epimutation of imprinted genes (Ishida et al. 2013).
PWS and AS are distinct neurogenetic disorders, both usually caused by chromosomal deletions on chromosome 15q11 or by uniparental disomy (UPD). In UPD, both copies of a chromosome are inherited from a single parent. These 15q11 chromosomal alterations result in an aberrant expression profile of gene loci that are subject to imprinting. Absence of a paternal allele of chromosome 15q11, due to a chromosomal deletion of (part of) the paternal allele or the presence of two imprinted copies due to maternal UPD, results in PWS. The absence of the maternal copy of the same region or paternal UPD causes AS. Table 4 contains an overview of the expected copy number changes and methylation profiles in PWS/AS patients with deletions or aberrant methylation. Rare disorders with similar clinical features as PWS but different genetic etiology have been identified and are often referred to as PWS-like disorders. One of these PWS-like syndromes is caused by MAGEL2 truncating mutations and was renamed from PWS-like syndrome to Schaaf-Yang syndrome (OMIM #615547).
Paternally expressed genes in the 15q11 PWS/AS region are MKRN3, MAGEL2, NDN, SNRPN and the snoRNA cluster; while UBE3A is maternally expressed. The PWS-AS Imprinting Centre (IC) (located upstream of the SNURF-SNRPN gene) contains both the PWS-SRO (smallest region of deletion overlap) and the AS-SRO. The AS-SRO is required for the PWS/AS region to have the maternal pattern of epigenetic modification and gene expression only if the chromosome has an intact PWS-SRO. The PWS-SRO is a 4.1 kb region that includes the SNRPN promoter. The PWS-SRO is unconditionally required for the PWS/AS region to have the paternal pattern of epigenetic modification and gene expression.
Finally, a rare cause of PWS is a small deletion within the SNORD116 cluster, downstream of SNRPN (Sahoo et al. 2008). However, this deletion is only relevant when it is absent in parental samples. Additional probes for the 15q11 region are present in the SALSA MLPA Probemix P343 Autism-1 and the SALSA MLPA Probemix P336 UBE3A, please note that these are research use only (RUO) assays.
Additionally, maternal duplications of the PWS/AS critical region on 15q11.2-q13.1 cause the 15q11 duplication syndrome characterized by developmental delay, intellectual disability, hypotonia, and seizures. The extra copy is most commonly a maternal isodicentric 15q11.2-q13.1 supernumerary chromosome (80% of cases) or a maternal interstitial 15q11.2-q13.1 duplication (20% of cases).
The database of genomic variants mentions that copy number changes in the breakpoint region BP1-BP2 (NIPA1 and TUBGCP5) and u1B-u1B (SNRPN exons 1 and 2) region have been found in healthy individuals (see http://dgv.tcag.ca/dgv/app/home). According to Stefansson et al. (2008), a deletion of the BP1-BP2 region is present in 0.19% of normal individuals and in 0.55% of schizophrenia patients. More probes for this BP1-BP2 region can be found in the SALSA MLPA Probemix P211 HSP region (RUO).
More information is available at:
https://www.ncbi.nlm.nih.gov/books/NBK1330/ (PWS),
https://www.ncbi.nlm.nih.gov/books/NBK1144/ (AS), and
https://www.ncbi.nlm.nih.gov/books/NBK367946/ (15q11 Duplication Syndrome).
SALSA MLPA Probemix ME028 Prader-Willi/Angelman is CE-marked for in vitro diagnostic (IVD) use. This assay has also been registered for IVD use in Colombia.
This assay is for research use only (RUO) in all other territories.
A general SALSA MLPA Reagent Kit and SALSA HhaI are required for MS-MLPA experiments (to be ordered separately).
These optional accessories can be ordered separately.
Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.
The commercially available positive samples below have been tested with the current (D1) version of this product and have been shown to produce useful results.